Cannabis in Poland
Medical OnlyOverview
Poland legalized medical cannabis in 2017, becoming one of the first Central European countries to establish a formal medical cannabis program. The law permits the use of cannabis-based medicines for patients with conditions where conventional treatments have proven insufficient, including chronic pain, multiple sclerosis spasticity, nausea and vomiting from chemotherapy, and treatment-resistant epilepsy.
Medical cannabis in Poland is available through pharmacies with a prescription and must be imported, as domestic cultivation for medical cannabis was not initially permitted. Imports come primarily from Canada, the Netherlands, and other licensed producers. The Polish medical cannabis market has grown significantly, driven by increasing physician awareness, growing patient demand, and expanding insurance coverage in some cases.
Poland's significance in the European cannabis market stems from its population — at 38 million, it is the fifth most populous EU member state. The medical cannabis patient base has expanded rapidly, making Poland one of the larger medical cannabis markets in Central and Eastern Europe. Several cannabis companies have established Polish operations focused on importation, distribution, and patient access programs.
Recreational cannabis remains illegal in Poland, and the conservative political landscape suggests legalization is unlikely in the near term. However, the successful growth of the medical program has shifted public attitudes, and younger demographics show stronger support for reform. Poland's proximity to Germany and the Czech Republic — both pursuing broader legalization — may also influence future policy direction.
Key Facts
- Medical cannabis legalized in 2017 — one of first Central European programs
- Cannabis products imported from Canada, Netherlands, and other producers
- 38 million population makes it a significant European market
- Rapidly growing medical cannabis patient base
- No domestic medical cannabis cultivation initially permitted
- Recreational cannabis remains illegal under conservative political environment
Recent Developments
Medical cannabis patient numbers growing rapidly
New import licenses being issued for additional product varieties
Domestic cultivation legislation being debated to reduce import dependence
Growing physician education programs improving prescribing rates
Investment Implications
Poland is one of the fastest-growing medical cannabis markets in Europe. Companies with Polish distribution and import licenses benefit from the expanding patient base and limited domestic supply. The large population creates scale potential as the medical program matures. Investors should watch for domestic cultivation authorization, which would change the competitive landscape. Proximity to reforming neighbors (Germany, Czech Republic) could accelerate broader policy shifts over time.